Vincent Nicolais, MD

Education

Dr. Nicolais’ research interests include immune modulation and antimicrobial agent effectiveness.

Investigator, Open-label, comparative, randomized, multicenter phase 1999-2001
III study of intravenous treatment of Synercid 7.5 mg/kg q 8 hours plus
Aztreonam 2G q 8 hours versus standard therapy in the treatment of
190 adult evaluable hospitalized patients with nosocomial pneumonia
due, at least in part, to gram positive cocci"
Investigator, RP59500V-396: Randomized, double-blind, comparative 1998-2000
study of the efficacy and safety of Synercid monotherapy regimens and
Syncercid in combination with Ampicillin in the treatment of
infection caused by Vancomycin-Resistant Enterococcus
Faecium (VREF).
Investigator, LY333328 vs Vancomycin in Skin/skin-Structure Infections 1998-1999
Investigator,Linezolid vs. Oxacillin Sodium/Dicloxacillin Sodium 1998-1999
for the Treatment of Complicated Skin and Soft Tissue Infections;
Investigator Linezolid in the Treatment of Patients 1998-1999
With Nosocomial Pneumonia: a Double-blind, Randomized,
Comparator-controlled study"
Investigator, "Compassionate Use of Linezolid 1998-1999
for Multi-drug Resistant Gram-positive Bacteria"
Principle Investigator, Open Study of Synercid (quinupristin/ 1998-1999
dalfopristin, RP59500) for Emergency Use (Infections Due to
Resistant Bacteria, Treatment Failure or in Treatment-Intolerant
Patients)
Principle Investigator, E-5 Monoclonal Antibody Study 1995-1997
$3000.00 stip

2005 Dr. Joseph and Rae Brown Award Presented by the National Society of Critical Care
Medicine for outstanding contributions to multidisciplinary
critical care on a local and regional level.
Principle Investigator, E-5 Monoclonal Antibody Study 1995-1997
$3000.00 stipend.